Print this page
-
Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 (in subjects with relapsed or refractory B-Cell Non-Hodgkin s Lymphoma (B-NHL)
Protocol: 012208Principal Investigator:
- Ira Braunschweig (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Other